Crinetics Pharmaceuticals Inc CRNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—ESI, CRNX, SOLS, and PATK
-
Are CRNX, VEEE, ESI Obtaining Fair Deals for their Shareholders?
-
Are ESI, CRNX, SOLS Obtaining Fair Deals for their Shareholders?
-
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
-
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
-
Cantor Sees 'Clear Strategic Rationale' Behind Vertex's Buy of Crinetics — Market Talk
-
Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
-
CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Trading Information
- Previous Close Price
- $83.91
- Day Range
- $83.81–83.98
- 52-Week Range
- $25.83–84.00
- Bid/Ask
- $83.50 / $84.15
- Shares Outstanding
- 105.84M
- Market Cap
- $8.88B
- Volume/Avg
- 4 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 449.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 594
- Website
- https://www.crinetics.com
Valuation
|
Metric
|
CRNX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.90 |
Price/Sales | 449.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CRNX
|
|---|---|
Quick Ratio | 18.25 |
Current Ratio | 18.60 |
Interest Coverage | — |
Quick Ratio
CRNX
Profitability
|
Metric
|
CRNX
|
|---|---|
Return on Assets (Normalized) | −31.07% |
Return on Equity (Normalized) | −34.32% |
Return on Invested Capital (Normalized) | −37.06% |
Return on Assets
CRNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%R!Xpc | LOCK|t>vK | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|twg#c< | LOCK|H#%B | $71B | |||
| argenx SE ADR
ARGX
| LOCK|gb@l<! | LOCK|ww | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H$TPC# | LOCK|F& | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|py<M^sx | LOCK|Q$hvY | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Zycmk$< | LOCK|nJ&J | $26B | |||
| Moderna Inc
MRNA
| LOCK|>Z>>$> | LOCK|&$F | $25B | |||
| Incyte Corp
INCY
| LOCK|r<!>Px | LOCK|gvJ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|xwNff$ | LOCK|?L | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|$kd?Y> | LOCK|w&$ | $16B |
United States